Study Could Widen Market For Cholesterol Treatments - WSJ.com

Two decades after the first cholesterol-lowering drug known as a statin hit the market, a major new study is poised to reshape the landscape for the world's best-selling class of medicines.Results of the trial, featuring AstraZeneca PLC's statin Crestor, will be presented next Sunday in New Orleans at the American Heart Association's annual scientific meeting. But it is already known it was a success: The 17,802-patient study was halted last spring, much earlier than expected, after a planned interim check found substantial reductions in deaths, heart attacks and other serious events among patients taking the drug compared with a placebo.

Study Could Widen Market For Cholesterol Treatments - WSJ.com